Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALD-101
- Development stage
- Discontinued
- Lead developer
- Aldagen
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ALD-101 is an investigational cell therapy consisting of a population of hematopoietic stem and progenitor cells (HSPCs) isolated from umbilical cord blood based on high expression of the enzyme aldehyde dehydrogenase (ALDH). Developed by Aldagen (later acquired by Cytomedix and Nuo Therapeutics), ALD-101 is designed as an adjuvant to standard unrelated umbilical cord blood transplantation (UCBT). The selection of "ALDH-bright" (ALDHbr) cells aims to provide a concentrated population of potent progenitor cells that can accelerate hematopoietic recovery, specifically reducing the time to neutrophil and platelet engraftment, which is a significant clinical challenge in cord blood transplants. It has been primarily evaluated in pediatric patients with inherited metabolic diseases (inborn errors of metabolism) undergoing transplant.
- Other names
- ALDH-bright cellsALDHbr cellsAldehyde dehydrogenase-bright cells
Beyond the preview
Go deeper on ALD-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALD-101.